Latest News by Industry
SAN FRANCISCO--(BUSINESS WIRE)--Nov 25, 2024--
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir Biotechnology’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241125578049/en/
CONTACT: Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bioInvestors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL AIDS HEALTH INFECTIOUS DISEASES CLINICAL TRIALS
SOURCE: Vir Biotechnology, Inc.
Copyright Business Wire 2024.
PUB: 11/25/2024 09:30 AM/DISC: 11/25/2024 09:32 AM
http://www.businesswire.com/news/home/20241125578049/en